title: Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study.
abstract: A two-arm randomized open labeled controlled clinical trial was conducted on 50 patients with non-alcoholic fatty liver disease (NAFLD). Participants were assigned to take either a lifestyle modification (LM), or LM +30 g/day brown milled flaxseed for 12 weeks. At the end of the study, body weight, liver enzymes, insulin resistance and hepatic fibrosis and steatosis decreased significantly in both groups (p< 0.05); however, this reduction was significantly greater in those who took flaxseed supplementation (p < 0.05). The significant mean differences were reached in hepatic markers between flaxseed and control group, respectively: ALT [-11.12 compared with -3.7 U/L; P< 0.001], AST [-8.29 compared with -4 U/L; p < 0.001], GGT [-15.7 compared with -2.62 U/L; p < 0.001], fibrosis score [-1.26 compared with -0.77 kPa; p = 0.013] and steatosis score [-47 compared with -15.45 dB/m; p = 0.022]. In conclusion, flaxseed supplementation plus lifestyle modification is more effective than lifestyle modification alone for NAFLD management.
authors.affiliation: a Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology , National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Science , Tehran , Iran ;
authors.forename: Zahra
authors.initials: Z
authors.lastname: Yari
authors.affiliation: b Department of Nutrition, Faculty of Nutrition and Dietetics , Tehran University of Medical Sciences , Tehran , Iran ;
authors.forename: Mehran
authors.initials: M
authors.lastname: Rahimlou
authors.affiliation: a Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology , National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Science , Tehran , Iran ;
authors.forename: Tannaz
authors.initials: T
authors.lastname: Eslamparast
authors.affiliation: c Digestive Disease Research Institute, ImamKhomeini Hospital , Tehran University of Medical Sciences , Tehran , Iran ;
authors.forename: Naser
authors.initials: N
authors.lastname: Ebrahimi-Daryani
authors.affiliation: d Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute , Tehran University of Medical Sciences , Tehran , Iran.
authors.forename: Hossein
authors.initials: H
authors.lastname: Poustchi
authors.affiliation: a Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology , National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Science , Tehran , Iran ;
authors.forename: Azita
authors.initials: A
authors.lastname: Hekmatdoost
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D003131:Combined Modality Therapy; D019587:Dietary Supplements; D054459:Elasticity Imaging Techniques; D005260:Female; D019597:Flax; D005500:Follow-Up Studies; D005511:Food Handling; D055951:Functional Food; D000070497:Healthy Lifestyle; D006801:Humans; D007333:Insulin Resistance; D007492:Iran; D008099:Liver / Q000000981:diagnostic imaging / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D010349:Patient Compliance; D010865:Pilot Projects; D012639:Seeds; D012720:Severity of Illness Index
chemical_list: D015415:Biomarkers
keywords: Clinical trial; flaxseed; hepatic fibrosis; liver enzymes; non-alcoholic fatty liver disease